Journal
CELL
Volume 176, Issue 6, Pages 1248-1264Publisher
CELL PRESS
DOI: 10.1016/j.cell.2019.01.021
Keywords
-
Categories
Funding
- NIH [R01-EY019287-06A1, R21-EY026707-02, R21-EY028701-01, P30-EY02687]
- Champalimaud Award
- Glenn Foundation for Medical Research Award
- Starr Foundation
- Jeffrey Fort Innovation Fund
- Edward N. and Della L. Thome Foundation Award
- Research to Prevent Blindness, New York, NY
- NATIONAL EYE INSTITUTE [P30EY002687] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The discovery of vascular endothelial-derived growth factor (VEGF) has revolutionized our understanding of vasculogenesis and angiogenesis during development and physiological homeostasis. Over a short span of two decades, our understanding of the molecular mechanisms by which VEGF coordinates neurovascular homeostasis has become more sophisticated. The central role of VEGF in the pathogenesis of diverse cancers and blinding eye diseases has also become evident. Elucidation of the molecular regulation of VEGF and the transformative development of multiple therapeutic pathways targeting VEGF directly or indirectly is a powerful case study of how fundamental research can guide innovation and translation. It is also an elegant example of how agnostic discovery and can transform our understanding of human disease. This review will highlight critical nodal points in VEGF biology, including recent developments in immunotherapy for cancer and multitarget approaches in neovascular eye disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available